Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL

Table 1 Relative MCL-1 and BAX mRNA expression levels post-treatment (21 days) with docetaxel (T), carboplatin (C), trastuzumab (H) and/or lapatinib (L) in HER2-positive breast tumours¹⁵

Pt no.	Treatment regimen	Fold change in mRNA post-treatment
Pt no.	Treatment regimen	MCL-1	BAX
TCHL_39	TCH	1.1	0.9
TCHL_45	TCH	1.6	0.7
TCHL_50	TCH	1.0	0.8
TCHL_6	TCH	1.4	1.2
TCHL_29	TCL	1.0	1.2
TCHL_44	TCHL	0.9	1.1
TCHL_54	TCHL	1.6	0.7
TCHL_7	TCHL	1.3	0.8

Tumours with an increase in MCL-1 (≥1.2) and a decrease in BAX (≤0.8) are highlighted in bold

ISSN: 1471-2407